PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
26.51%
Revenue growth of 26.51% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
674.09%
Gross profit growth of 674.09% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
92.54%
Positive EBIT growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might see a strong competitive advantage in operations.
92.54%
Positive operating income growth while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch would spot a big relative advantage here.
89.98%
Positive net income growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would view this as a notable competitive advantage.
90.72%
EPS growth of 90.72% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
90.72%
Diluted EPS growth of 90.72% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could improve over time.
6.68%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.68%
Diluted share change of 6.68% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
334.00%
OCF growth of 334.00% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
260.05%
FCF growth of 260.05% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
480.08%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.08%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
-38.62%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 9.80%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
1711.87%
OCF/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.00% over 10 years. Joel Greenblatt would verify if a unique competitive moat underlies these cash flows.
360.13%
OCF/share CAGR of 360.13% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
543.04%
3Y OCF/share growth > 1.5x Drug Manufacturers - Specialty & Generic median of 6.59%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
-16516.68%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 15.80%. Seth Klarman might see a fundamental problem if peers maintain growth.
-737.15%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
38.51%
3Y net income/share CAGR near Drug Manufacturers - Specialty & Generic median. Charlie Munger sees standard sector-level performance in the last few years.
5797.52%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 38.69% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
5.79%
5Y equity/share CAGR 1.25-1.5x Drug Manufacturers - Specialty & Generic median. Mohnish Pabrai might see disciplined retention of earnings behind outperformance.
-7.21%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 1.14%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.06%
AR growth of 10.06% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
-1.11%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-1.57%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-8.38%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-2.25%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
5.26%
R&D growth of 5.26% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
22.38%
SG&A growth of 22.38% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.